Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 11/20 | 0.34 |
| ▸ | NPY1R | P25929 | 9/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.34 |
| ▸ | NPY2R | P49146 | 5/20 | 0.34 |
| ▸ | TACR2 | P21452 | 2/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20791913 | 0.92 | CYP2D6 (0.38) | KDM4ELMNACYP2C19SMN1; SMN2EPHA2 | |
| SCHEMBL17619899 | 0.91 | WNT3A (0.38) | KDM4ELMNASMN1; SMN2TACR2WNT3A | |
| SCHEMBL17619932 | 0.90 | SMN1; SMN2 (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL18591492 | 0.83 | KDM4E (0.34) | KDM4ENPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL17620032 | 0.82 | HRH4 (0.36) | LMNANPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL21546370 | 0.81 | GAA (0.42) | KDM4ELMNATACR2WNT3AGAA | |
| SCHEMBL18591496 | 0.76 | POLB (0.33) | KDM4ECYP1A2TACR2GAA | |
| SCHEMBL17620047 | 0.74 | KDM4E (0.39) | KDM4ENPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL17619962 | 0.73 | PADI4 (0.38) | — | |
| SCHEMBL21546358 | 0.73 | NPY4R (0.35) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | KDM4E 274/4885LMNA 3981/4885NPC1 732/4885 |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | KDM4E 274/4885LMNA 3981/4885NPC1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.